pharma · Thyroid eye disease · Thyroid Eye Disease · VRDN
Viridian Pharma
Viridian Pharma Ltd
Viridipharm is a pharma organization headquartered in Elmwood Park, USA. It trades on NYSE under ticker VRDN. Primary therapeutic focus areas include Thyroid eye disease, Thyroid Eye Disease, Thyroid eye disease (TED), T
Company details
- Status
- Public
- HQ
- 200 Market Street, ELMWOOD PARK, NJ 07407, US
- Founded
- 2017
- Employees
- 2
- Programs
- 13
- Drugs
- 11
- Patents
- 3
Quick answer
Viridipharm is a pharma organization headquartered in Elmwood Park, USA. It trades on NYSE under ticker VRDN. Primary therapeutic focus areas include Thyroid eye disease, Thyroid Eye Disease, Thyroid eye disease (TED), Thyroid Eye Disease (TED). NovaPharmaNews links 13 clinical program(s), 1 drug profile(s), and 3 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (13).
Company snapshot
We believe that small plants can make a big difference. Viridipharm’s mission has always been simple: to harmonize cutting-edge science with natural ingredients. We believe that CBD is a gift from nature, so we have taken it upon ourselves to ensure the integrity of the plant remains intact to help as many people as possible. To do this, we only offer high-quality CBD in all of our pharmacist-form
- 2 approved product(s) across US/EU regulatory metadata.
- 13 active pipeline program(s) linked via ClinicalTrials.gov.
- 3 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Viridian Pharma. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition
- deal
Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM
Recent coverage
Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM
Vir Biotechnology is undergoing significant leadership changes post-AGM, with a board reshuffle and key governance votes set to influence its strategic direction. Investors and pharmaceutical BD teams should monitor these developments for potential shifts in clinical trial focus and market positioning.
Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition
Gilead Sciences has achieved a significant milestone with the FDA approval of bulevirtide, the first drug to treat chronic hepatitis D. This landmark decision intensifies the competitive landscape as Bay Area rivals Vir Biotechnology and Mirum Pharmaceuticals advance their own therapies.
Top assets
Lead pipeline drugs
- approved
- approved
- approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Congress & presentations
- CongressDrug Discovery USA
- PresentationPhase 1 clinical trial data of VRDN-008 in healthy volunteers
Momentum
Proprietary activity score for Viridian Pharma.
3 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Recent activity
Latest pipeline, patent, and corporate events for Viridian Pharma.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Viridian Pharma?
-
Is Viridian Pharma publicly traded?
-
What drugs does Viridian Pharma develop or market?
-
What are the latest developments for Viridian Pharma?
-
What therapeutic areas does Viridian Pharma focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.